Lenvatinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor, it inhibits vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2 and VEGFR3, as well as other RTKs associated with pathological neovascularization, tumor growth and cancer progression (Decraecker et al., 2021). This evidence concerns the gene FLT1 and neoplasm.